{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:32:57Z","timestamp":1740137577777,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017A030313560"],"award-info":[{"award-number":["2017A030313560"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Dual antiplatelet therapy can reduce coronary thrombosis and improve the prognosis in patients with acute coronary syndrome (ACS). However, there was limited prognostic information about fibrinolytic dysregulation in patients with ACS. This study is aimed to evaluated the prevalence and impact of fibrinolytic dysregulation in patients with acute coronary syndrome (ACS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analyzed coagulation and fibrinolysis related indexes of ACS in hospitalized adults with rapid thrombelastography between May 2016 and December 2018. All of the follow-up visits were ended by December 2019. The primary outcome was the occurrence of major adverse cardiovascular events (MACEs), which included unstable angina pectoris, non-fatal myocardial infarction, non-fatal cerebral infarction, heart failure and all-cause death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three hundred thirty-eight patients were finally included with an average age of 62.5\u2009\u00b1\u200912.8\u2009years old, 273 (80.5%) were males, 137(40.5%) patients were with ST-elevation myocardial infraction. Fibrinolysis shutdown (LY30&lt;0.8%) and hyperfibrinolysis (LY30 &gt;3.0%) were observed among 163 (48.2%) and 76(22.5%) patients, respectively. During a total of 603.2 person\u00b7years of follow-up period, <jats:bold>77<\/jats:bold> MACEs occurred (22.8%). Multivariate Cox regression analysis indicated that LY30 [HR: 1.101, 95% CI: 1.010\u20131.200, <jats:italic>P<\/jats:italic>\u2009=\u20090.028] was independently correlated with the occurrence of MACEs. The hazard ratios pertaining to MACEs in patients with fibrinolysis shutdown and hyperfibrinolysis compared with those in the physiologic range (LY30: 0.8\u20133.0%) were 1.196 [HR: 1.196, 95% CI: 0.679\u20132.109,<jats:italic>P<\/jats:italic>\u2009=\u20090.535] and 2.275 [HR: 2.275, 95% CI: 1.241\u20134.172, <jats:italic>P<\/jats:italic>\u2009=\u20090.003], respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Fibrinolytic dysregulation is very common in selected patients with ACS, and hyperfibrinolysis (LY30\u2009&gt;\u20093%) is associated with poor outcomes in patients with ACS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12959-021-00288-5","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T13:02:53Z","timestamp":1621688573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and impact of fibrinolytic dysregulation in patients with acute coronary syndromes"],"prefix":"10.1186","volume":"19","author":[{"given":"Huaibin","family":"Wan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenbang","family":"Lie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohui","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"issue":"39","key":"288_CR1","first-page":"119","volume":"2018","author":"B Ibanez","year":"2017","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2017;2018(39):119\u201377.","journal-title":"Eur Heart J"},{"issue":"53","key":"288_CR2","first-page":"34","volume":"2018","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardio Thorac Surg. 2017;2018(53):34\u201378.","journal-title":"Eur J Cardio Thorac Surg"},{"key":"288_CR3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/SLA.0b013e3182658180","volume":"256","author":"JB Holcomb","year":"2012","unstructured":"Holcomb JB, Minei KM, Scerbo ML, Radwan ZA, Wade CE, Kozar RA, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg. 2012;256:476\u201386.","journal-title":"Ann Surg"},{"key":"288_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jpedsurg.2013.03.036","volume":"48","author":"AM Vogel","year":"2013","unstructured":"Vogel AM, Radwan ZA, Cox CJ, Cotton BA. Admission rapid thrombelastography delivers real-time \u201cactionable\u201d data in pediatric trauma. J Pediatr Surg. 2013;48:1371\u20136.","journal-title":"J Pediatr Surg"},{"key":"288_CR5","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/CCM.0000000000003730","volume":"47","author":"Y Harahsheh","year":"2019","unstructured":"Harahsheh Y, Duff OC, Ho KM. Thromboelastography predicts thromboembolism in critically ill coagulopathic patients. Crit Care Med. 2019;47:826\u201332.","journal-title":"Crit Care Med"},{"key":"288_CR6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.21037\/jtd.2019.04.39","volume":"11","author":"C Li","year":"2019","unstructured":"Li C, Zhao Q, Yang K, Jiang L, Yu J. Thromboelastography or rotational thromboelastometry for bleeding management in adults undergoing cardiac surgery. J Thorac Dis. 2019;11:1170\u201381.","journal-title":"J Thorac Dis"},{"key":"288_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.15171\/jcvtr.2019.48","volume":"11","author":"E Khalaf-Adeli","year":"2019","unstructured":"Khalaf-Adeli E, Alavi M, Alizadeh-Ghavidel A, Pourfathollah AA. Comparison of standard coagulation testing with thromboelastometry tests in cardiac surgery. J Cardiovasc Thorac Res. 2019;11:300\u20134.","journal-title":"J Cardiovasc Thorac Res"},{"key":"288_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jamcollsurg.2016.01.006","volume":"222","author":"HB Moore","year":"2016","unstructured":"Moore HB, Moore EE, Liras IN, Gonzalez E, Harvin JA, Holcomb JB, et al. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality. J Am Coll Surg. 2016;222:347\u201355.","journal-title":"J Am Coll Surg"},{"key":"288_CR9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.surg.2015.05.004","volume":"158","author":"IN Liras","year":"2015","unstructured":"Liras IN, Cotton BA, Cardenas JC, Harting MT. Prevalence and impact of admission hyperfibrinolysis in severely injured pediatric trauma patients. Surgery. 2015;158:812\u20138.","journal-title":"Surgery."},{"key":"288_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jamcollsurg.2016.12.046","volume":"224","author":"IN Liras","year":"2017","unstructured":"Liras IN, Caplan HW, Stensballe J, Wade CE, Cox CS, Cotton BA. Prevalence and impact of admission acute traumatic coagulopathy on treatment intensity, resource use, and mortality. J Am Coll Surg. 2017;224:625\u201332.","journal-title":"J Am Coll Surg"},{"key":"288_CR11","doi-asserted-by":"publisher","first-page":"3470145","DOI":"10.1155\/2019\/3470145","volume":"2019","author":"W Peng","year":"2019","unstructured":"Peng W, Shi X, Xu X, Lin Y. Both CYP2C19 and PON1 Q192R genotypes influence platelet response to clopidogrel by thrombelastography in patients with acute coronary syndrome. Cardiovasc Ther. 2019;2019:3470145.","journal-title":"Cardiovasc Ther"},{"key":"288_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ddr.21112","volume":"74","author":"A Bitar","year":"2013","unstructured":"Bitar A, Kreutz RP. Role of thrombelastography (TEG) in risk assessment and guidance of antithrombotic therapy in patients with coronary artery disease. Drug Develop Res. 2013;74:533\u201340.","journal-title":"Drug Develop Res"},{"issue":"37","key":"288_CR13","first-page":"267","volume":"2016","author":"M Roffi","year":"2015","unstructured":"Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2015;2016(37):267\u2013315.","journal-title":"Eur Heart J"},{"key":"288_CR14","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1097\/00029330-201409200-00011","volume":"127","author":"L Xu","year":"2014","unstructured":"Xu L, Wang L, Yang X, Li K, Sun H, Zhang D, et al. Platelet function monitoring guided antiplatelet therapy in patients receiving high-risk coronary interventions. Chin Med J. 2014;127:3364\u201370.","journal-title":"Chin Med J"},{"key":"288_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jacc.2006.10.050","volume":"49","author":"KP Bliden","year":"2017","unstructured":"Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2017;49:657\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"288_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1080\/09537104.2017.1280147","volume":"28","author":"S Rafiq","year":"2017","unstructured":"Rafiq S, Johansson PI, Kofoed KF, Lund JT, Olsen PS, Bentsen S, et al. Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial). Platelets. 2017;28:786\u201393.","journal-title":"Platelets."}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00288-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-021-00288-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00288-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T13:08:35Z","timestamp":1621688915000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-021-00288-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["288"],"URL":"https:\/\/doi.org\/10.1186\/s12959-021-00288-5","relation":{},"ISSN":["1477-9560"],"issn-type":[{"type":"electronic","value":"1477-9560"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"17 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Dongguan people\u2019s hospital approved this retrospective study. Written informed consent was obtained from all included patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}